Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Ho Chi Minh City plans to pilot mechanisms for pharmaceutical companies to adopt digital technologies, showcasing its ...

The latest health news includes Robert F. Kennedy Jr.'s nomination, Abbott's strategy amid global challenges, and Purdue Pharma's opioid settlement. It highlights company strategies, profits, and ...

The CEO of Germany's Merck KGaA on Thursday said a recovery in sales growth at its existing business means it can take a cautious approach to buying other companies, which are expensively priced. "We ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.